Cyclacel Pharmaceuticals Inc
CYCC6.365USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.08MMarket Cap
LossP/E TTM
More Details of Cyclacel Pharmaceuticals Inc Company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Cyclacel Pharmaceuticals Inc Info
Ticker SymbolCYCC
Company nameCyclacel Pharmaceuticals Inc
IPO dateJan 01, 1996
CEODatuk Sing Ee (Doris) Wong
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 01
Address200 Connell Dr Ste 1500
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07922-2811
Phone19085177330
Websitehttps://cyclacel.com/
Ticker SymbolCYCC
IPO dateJan 01, 1996
CEODatuk Sing Ee (Doris) Wong
Company Executives of Cyclacel Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Cu Seng Kiu
Mr. Cu Seng Kiu
Chief Financial Officer, Executive Director, Company Secretary
Chief Financial Officer, Executive Director, Company Secretary
200.00K
--
Ms. Soon Ping (Zara) Pappas
Ms. Soon Ping (Zara) Pappas
Independent Director
Independent Director
--
--
Dr. Satis Waran Nair Krishnan
Dr. Satis Waran Nair Krishnan
Independent Director
Independent Director
--
--
Ms. Inigo Angel Laurdura
Ms. Inigo Angel Laurdura
Independent Director
Independent Director
--
--
Datuk Sing Ee (Doris) Wong
Datuk Sing Ee (Doris) Wong
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Cu Seng Kiu
Mr. Cu Seng Kiu
Chief Financial Officer, Executive Director, Company Secretary
Chief Financial Officer, Executive Director, Company Secretary
200.00K
--
Ms. Soon Ping (Zara) Pappas
Ms. Soon Ping (Zara) Pappas
Independent Director
Independent Director
--
--
Dr. Satis Waran Nair Krishnan
Dr. Satis Waran Nair Krishnan
Independent Director
Independent Director
--
--
Ms. Inigo Angel Laurdura
Ms. Inigo Angel Laurdura
Independent Director
Independent Director
--
--
Datuk Sing Ee (Doris) Wong
Datuk Sing Ee (Doris) Wong
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United Kingdom
43.00K
0.00%
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Doris (Sing Ee Wong)
22.68%
Kua (Khai Loon)
9.54%
Ong (Yee Lung)
9.54%
Yap (Kim Choy)
9.54%
Loon (Kua Khai)
6.90%
Other
41.80%
Shareholders
Shareholders
Proportion
Doris (Sing Ee Wong)
22.68%
Kua (Khai Loon)
9.54%
Ong (Yee Lung)
9.54%
Yap (Kim Choy)
9.54%
Loon (Kua Khai)
6.90%
Other
41.80%
Shareholder Types
Shareholders
Proportion
Individual Investor
62.28%
Corporation
5.70%
Hedge Fund
0.02%
Other
32.00%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
31
22.23K
1.06%
-84.00K
2025Q2
44
1.08M
68.06%
-871.00
2025Q1
48
12.37M
94.62%
+136.01K
2024Q4
47
784.10K
10.08%
+245.30K
2024Q3
53
389.51K
24.87%
-264.17K
2024Q2
57
525.53K
40.85%
-21.53K
2024Q1
63
332.54K
28.64%
-115.98K
2023Q4
64
360.14K
34.53%
-35.53K
2023Q3
66
245.38K
29.33%
-201.47K
2023Q2
66
305.33K
36.58%
-181.83K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Doris (Sing Ee Wong)
810.95K
23.19%
--
--
Jul 10, 2025
Kua (Khai Loon)
385.41K
11.02%
+385.41K
--
Sep 05, 2025
Ong (Yee Lung)
404.46K
11.56%
+186.47K
+85.53%
Sep 04, 2025
Yap (Kim Choy)
404.46K
11.56%
+186.47K
+85.53%
Sep 04, 2025
Loon (Kua Khai)
218.00K
6.23%
--
--
Sep 01, 2025
Fitters Diversified Bhd
699.16K
19.99%
+699.16K
--
Sep 12, 2025
Tower Research Capital LLC
387.00
0.01%
+361.00
+1388.46%
Jun 30, 2025
UBS Financial Services, Inc.
399.00
0.03%
+140.00
+54.05%
Jun 30, 2025
Osaic Holdings, Inc.
1.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Apr 14, 2020
Merger
20→1
Apr 14, 2020
Merger
20→1
Date
Type
Ratio
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Apr 14, 2020
Merger
20→1
Apr 14, 2020
Merger
20→1
Apr 14, 2020
Merger
20→1
Apr 14, 2020
Merger
20→1
FAQs
Who are the top five shareholders of Cyclacel Pharmaceuticals Inc?
The top five shareholders of Cyclacel Pharmaceuticals Inc are:
Doris (Sing Ee Wong) holds 810.95K shares, accounting for 23.19% of the total shares.
Kua (Khai Loon) holds 385.41K shares, accounting for 11.02% of the total shares.
Ong (Yee Lung) holds 404.46K shares, accounting for 11.56% of the total shares.
Yap (Kim Choy) holds 404.46K shares, accounting for 11.56% of the total shares.
Loon (Kua Khai) holds 218.00K shares, accounting for 6.23% of the total shares.
Doris (Sing Ee Wong) holds 810.95K shares, accounting for 23.19% of the total shares.
Kua (Khai Loon) holds 385.41K shares, accounting for 11.02% of the total shares.
Ong (Yee Lung) holds 404.46K shares, accounting for 11.56% of the total shares.
Yap (Kim Choy) holds 404.46K shares, accounting for 11.56% of the total shares.
Loon (Kua Khai) holds 218.00K shares, accounting for 6.23% of the total shares.
What are the top three shareholder types of Cyclacel Pharmaceuticals Inc?
The top three shareholder types of Cyclacel Pharmaceuticals Inc are:
Doris (Sing Ee Wong)
Kua (Khai Loon)
Ong (Yee Lung)
Doris (Sing Ee Wong)
Kua (Khai Loon)
Ong (Yee Lung)
How many institutions hold shares of Cyclacel Pharmaceuticals Inc (CYCC)?
As of 2025Q3, 31 institutions hold shares of Cyclacel Pharmaceuticals Inc, with a combined market value of approximately 22.23K, accounting for 1.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -66.99%.
What is the biggest source of revenue for Cyclacel Pharmaceuticals Inc?
In FY2024, the -- business generated the highest revenue for Cyclacel Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
